Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden

Acta Oncologica

Volumn 49, Issue 6, 2010, Pages 844-850

  Wilking, Ulla ^a   Jönsson, Bengt ^b   Wilking, Nils ^a   Bergh, Jonas ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; COMPARATIVE STUDY; DRUG MARKETING; DRUG USE; EARLY CANCER; FEMALE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; SWEDEN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; SWEDEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954473201     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.492790     Document Type: Article

References (24)

1. Nystr öm L, Andersson I, Bjurstam N. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002;359(9310):909-919
2. EBCTG. Efffect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365: 1687-1717
3. Ryden L, Haglund M, Bendahl P-O, Hatschek T, Kolaric A, Kovacs A, et al. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - A national survey performed at pathology departments in Sweden. Acta Oncol 2009;48:860-866
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relaps and survival with amplifi cation of the HER2/neu oncogene. Science 1987;235(4785):177-182
5. Fehm T, Jager W, Kraemer S, Sohn C, Solomayer-Meyberg G, Solomayer EF, et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res 2004;24:4205-4210
6. Ross JS, Fletcher JA, Linette GP, Clark JSE, Ayers M, Symmans WF, et al. The HER2 gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003;8:307-325
7. Slamon, DJ, Leyland-Jones B, Shalk S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2/neu/NEU for metastatic breast cancer that overexpresses HER2/neu/NEU. N Engl J Med 2001;344:783-792
8. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. Randomised phase II trial (M77001) of trastuzumab (Herceptin ® ) plus docetaxel versus docetaxel alone, as fi rst-line therapy in patients with HER2/neu/ NEU-positive metastatic breast cancer. J Clin Oncol 2005; 23:4247-4250
9. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl Med 2005;353: 1659-1672 (Pubitemid 41464705)
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy in operable HER2 positive breast cancer. N Engl J Med 2005;353:1673-1684
11. Slamon D, Eiermann W, Robert N, Pienowski T, Martin M, Rolski J, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC →T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC →TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. SABCS 2009 Abstract 62.
12. Swedish Breast Cancer Group. Available from: http://www. swebcg.roc.se.
13. Statistics Sweden. Statistiska centralbyrå n . Available from: http://www.scb.se.
14. National Board of Health and Welfare. Available from: http:// www.socialstyrelsen.se.
15. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE. Trastuzumab beyond progression in human epidermal growth factor receptor 2 - positive advanced breast cancer: A german breast group 26/Breast International Group 03-05 Study. J Clin Oncol 2009;27:1999-2006.
16. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl Med 2006;354:809-820
17. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685-5692 Epub 2009 Nov 2.
18. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, et al. Clinical relevance of HER2 overexpression/ amplifi cation in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693-5699
19. Gonzalez-Angulo A, Litton J, Broglio C, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2 - positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700-5706
20. Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, et al. A population-based study on the fi rst forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden. Acta Oncol 2002;41:276-281
21. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26:1231-1238 Epub 2008 Feb 4.
22. Lidgren M, Wilking N, Jö n sson B. Cost of breast cancer in Sweden 2002. Eur J Health Econ 2007;8:5-15.
23. Lidgren M, J ön sson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487-495 Epub 2007 Dec 6.
24. Lidgren M, Wilking N, J ön sson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008;47:1018-1028